Trial
NCT03787095
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Regeneron Pharmaceuticals
Condition
HIV Infections
Intervention
Cemiplimab
Why stopped
Stopped by monitoring committee recommendation due to adverse events
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-02